Literature DB >> 19832732

Intravitreal gas injection for macular hole with localized retinal detachment in highly myopic patients.

Fang-Ting Chen1, Po-Ting Yeh, Chang-Ping Lin, Muh-Shy Chen, Chang-Hao Yang, Chung-May Yang.   

Abstract

PURPOSE: This study aimed to evaluate treatment effects of intravitreal gas for macular hole with localized retinal detachment (RD) in highly myopic eyes and to examine how the vitreomacular relationship and other factors may influence treatment outcomes.
METHODS: Twenty highly myopic patients with macular holes and localized posterior RD, treated initially with intravitreal injection of C(3) F(8) , were prospectively studied. Recurrent disease was treated with repeated gas injection or vitrectomy according to the extent of detachment. Length of follow-up was ≥ 12 months. Vitreomacular conditions were determined before and within 2 months after gas injection by standard optical coherence tomography. Demographics, refractive errors, axial length, the extent of chorioretinal (CR) atrophy and visual acuity were recorded.
RESULTS: The success rate after primary gas injection was 70%. The remaining 30% of patients achieved anatomic success after further treatment, including vitrectomy with gas or silicone oil tamponade and/or scleral buckling. All cases achieved anatomic success after a mean of 1.4 surgeries. Univariate analysis showed that the patterns of the posterior vitreoretinal relationship did not differ significantly between those successfully treated with gas only (group 1) and those requiring vitrectomy (group 2) (p = 1.000). Logistic regression showed no statistically significant differences in any characteristics between groups 1 and 2.
CONCLUSIONS: Intravitreal gas tamponade alone may achieve anatomic success in more than two-thirds of highly myopic patients with macular holes and localized RD. Patients with different clinical characteristics and vitreoretinal relationships seem to have similar opportunities to achieve reattachment through this relatively non-invasive surgery.
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 19832732     DOI: 10.1111/j.1755-3768.2009.01649.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  7 in total

1.  Utility of microscope-integrated optical coherence tomography (MIOCT) in the treatment of myopic macular hole retinal detachment.

Authors:  Atul Kumar; Prateek Kakkar; Raghav Dinesh Ravani; Ashish Markan
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Gas tamponade for myopic foveoschisis with foveal detachment.

Authors:  Ting-Yu Wu; Chang-Hao Yang; Chung-May Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-10       Impact factor: 3.117

3.  The development and evolution of full thickness macular hole in highly myopic eyes.

Authors:  C-W Lin; T-C Ho; C-M Yang
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775

Review 4.  Vitreous tamponades in highly myopic eyes.

Authors:  X Valldeperas; J Lorenzo-Carrero
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

5.  Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes.

Authors:  Michael A Apolinario; Shaun I R Lampen; Tien P Wong; Christopher R Henry; Charles C Wykoff
Journal:  Am J Ophthalmol Case Rep       Date:  2019-07-05

Review 6.  Tamponade or filling effect: changes of forces in myopic eyes.

Authors:  Francesco Semeraro; Francesco Morescalchi; Andrea Russo; Mario R Romano; Ciro Costagliola
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

Review 7.  Internal limiting membrane peeling and gas tamponade for myopic foveoschisis: a systematic review and meta-analysis.

Authors:  Bo Meng; Lu Zhao; Yi Yin; Hongyang Li; Xiaolei Wang; Xiufen Yang; Ran You; Jialin Wang; Youjing Zhang; Hui Wang; Ran Du; Ningli Wang; Siyan Zhan; Yanling Wang
Journal:  BMC Ophthalmol       Date:  2017-09-08       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.